Glytrin-Met Tablet ER
Images are for reference. Actual packaging may vary.
Metformin (500mg) + Teneligliptin (20mg)
1 units • Other
A valid prescription is required for this medicine.
Haven’t found an alternative? A health advisor can help you understand what to do next.
We haven't found a cheaper matching alternative in our catalogue right now. Our health advisors can help you explore other options.
Active composition
+1 more active ingredient
Teneligliptin inhibits DPP-4, increasing incretin levels and enhancing insulin secretion.
Metformin reduces hepatic glucose production and enhances peripheral insulin sensitivity, lowering blood glucose levels.
Medical applications
Glytrin-Met Tablet ER is a combination oral antidiabetic medication containing Metformin 500 mg and Teneligliptin 20 mg, formulated for extended release to improve glycemic control in patients with type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, enhancing insulin sensitivity, and improving peripheral glucose uptake and utilization.
Teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases incretin levels, thereby stimulating insulin secretion and suppressing glucagon release in a glucose-dependent manner. The extended-release formulation allows for once-daily dosing, promoting better patient adherence and stable plasma drug concentrations. Glytrin-Met Tablet ER is indicated as an adjunct to diet and exercise to improve glycemic control in adults inadequately controlled on metformin alone or in combination with other antidiabetic agents.
It should be used cautiously in patients with renal impairment, hepatic dysfunction, or a history of lactic acidosis. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, which often diminish with continued use. Regular monitoring of blood glucose levels, renal function, and potential side effects is recommended during therapy.
Glytrin-Met Tablet ER offers a synergistic approach to managing hyperglycemia by targeting multiple pathophysiological defects in type 2 diabetes.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Side-effect information is not available for this medicine. Please consult your doctor or pharmacist.
Glytrin-Met Tablet ER may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
High Risk
Glytrin-Met Tablet ER is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Medical Advice
Glytrin-Met Tablet ER should be used with caution in patients with kidney disease. Dose adjustment of Glytrin-Met Tablet ER may be needed. Please consult your doctor. Use of Glytrin-Met Tablet ER is, however, not recommended in patients with severe kidney disease. Regular monitoring of kidney function test is advisable while you are taking this medicine.
Exercise Caution
It is not known whether Glytrin-Met Tablet ER alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
Consult Doctor
Glytrin-Met Tablet ER is probably unsafe to use in patients with liver disease and should be avoided. Please consult your doctor.
Regular Checkup
0 reviews for Glytrin-Met Tablet ER






